,,ii #aacth ,,congress #ast ,session ,s4 #hfe ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,may #f1 #bjac ,mr4 ,whitehouse 7for himself1 ,mr4 ,heller1 ,mr4 ,warner1 ,mr4 ,grassley1 ,mr4 ,brown1 ,mr4 ,reed1 ,mr4 ,begich1 ,mr4 ,casey1 and ,mr4 ,franken7 introduced the following bill2 which was read twice and referred to the ,committee on ,health1 ,education1 ,labor1 and ,pensions ,a ,,bill ,to provide for the establishment of a ,commission to ,accelerate the ,end of ,breast ,cancer4 #a4 ,short title2 table of contents 7a7 ,short title ,this ,act may be cited as the ,accelerating the ,end of ,breast ,cancer ,act of #bjac4 7b7 ,table of contents ,the table of contents of this ,act is as follows3 ,sec4 #a4 ,short title2 table of contents4 ,sec4 #b4 ,findings4 ,sec4 #c4 ,establishment4 ,sec4 #d4 ,purpose2 duties4 ,sec4 #e4 ,membership4 ,sec4 #f4 ,powers4 ,sec4 #g4 ,chairperson2 program managers4 ,sec4 #h4 ,coordination and nonduplication4 ,sec4 #i4 ,evaluation of the ,commission4 ,sec4 #aj4 ,authorization of funding4 ,sec4 #aa4 ,termination4 #b4 ,findings ,congress makes the following findings3 7#a7 ,in the ,united ,states1 the chance of a woman developing breast cancer during her lifetime has increased from #a in #aa in #aige to #a in #h today4 7#b7 ,worldwide1 breast cancer is the most frequently diagnosed cancer in women with #a1cjj1jjj cases each year4 ,breast cancer is also the leading cause of cancer death in women1 with more than #dch1jjj women dying from the disease worldwide in #bjaj1 a #cg4e percent increase since #aiij4 7#c7 ,more than #ij percent of deaths from breast cancer are caused by metastasis1 which occurs when cancerous cells spread to other organs or bone4 7#d7 ,the ,national ,cancer ,institute estimated that breast cancer care in the ,united ,states cost #af1ejj1jjj1jjj in #bjaj1 and cost the ,nation #ab1ajj1jjj1jjj in lost productivity4 7#e7 ,over the past #dj years1 very little has improved the incidence1 morbidity1 and mortality rates of breast cancer4 7#f7 ,in recognition of the complexity of breast cancer1 experts have identified the need to transform how research is conducted by engaging investigators from many disciplines4 7#g7 ,advances in understanding the progression of breast cancer1 particularly metastasis1 have the potential to translate to better understanding and preventing the spread of other types of cancer4 #c4 ,establishment ,there shall be established a commission to be known as the ,commission to ,accelerate the ,end of ,breast ,cancer 7in this ,act referred to as the ,commission74 #d4 ,purpose2 duties 7a7 ,purpose ,the purpose of the ,commission shall be to help end breast cancer by ,january #a1 #bjbj4 7b7 ,duties 7#a7 ,in general ,the ,commission shall identify1 recommend1 and promote initiatives1 partnerships1 and research within the public and private sectors1 basic and applied sciences1 and epidemiology that can be turned into strategies to prevent breast cancer and breast cancer metastasis4 7#b7 ,priority ,the ,commission shall give priority to initiatives1 partnerships1 and research that are-- 7,a7 not prioritized within the public sector2 and 7,b7 unlikely to be achieved by the private sector due to technical and financial uncertainty4 7c7 ,strategic plan ,not later than #f months after the appointment of the initial members of the ,commission1 the ,commission shall submit to the ,president and to the relevant authorizing and appropriations committees of ,congress1 a description of the ,commission's strategic plan to advance the purpose described in subsection 7a74 7d7 ,annual report ,not later than ,january #ae1 #bjad1 and annually thereafter1 the ,commission shall submit an annual report to the ,president1 ,congress1 and the public-- 7#a7 describing the ,commission's activities under this section1 including its progress in achieving the purpose described in subsection 7a72 and 7#b7 containing a full financial report1 including a line item report of the ,commission's expenditures for the preceding year4 #e4 ,membership 7a7 ,number2 appointment ,the ,commission shall be composed of not more than #aj members who shall be appointed by the ,president1 with the advice and consent of the ,senate1 not later than #fj days after the date of enactment of this ,act1 in accordance with this section4 7b7 ,representation 7#a7 ,in general ,each member of the ,commission shall be appointed to represent one of the following #c categories3 7,a7 ,individuals who represent the interests of varied disciplines within the biomedical research field4 7,b7 ,individuals who represent the relevant varied disciplines outside of the biomedical research field4 7,c7 ,patient advocates1 including individuals who-- 7i7 represent a patient-led1 patient-centered organization with a patient constituency either directly related to or relevant to breast cancer2 and 7ii7 are trained1 knowledgeable1 and prepared to participate in the decision-making process of science and medicine4 7#b7 ,representation of membership categories ,of the members of the ,commission-- 7,a7 at least #a1 but not more than #c1 shall be appointed to represent the category described in paragraph 7#a77;,a72 7,b7 at least #a1 but not more than #c1 shall be appointed to represent the category described in paragraph 7#a77;,b72 and 7,c7 at least #b1 but not more than #d1 shall be appointed to represent the category described in paragraph 7#a77;,c74 7c7 ,terms 7#a7 ,in general ,each member of the ,commission shall be appointed for a term of #c years and may be reappointed4 7#b7 ,vacancies ,any member of the ,commission appointed to fill a vacancy occurring before the expiration of the term for which the member's predecessor was appointed shall be appointed only for the remainder of that term4 ,a member may serve after the expiration of that member's term until a successor has taken office4 ,a vacancy in the ,commission shall be filled in the manner in which the original appointment was made and shall not affect the power of the remaining members to execute the duties of the ,commission4 7d7 ,quorum ,three members of the ,commission shall constitute a quorum4 #f4 ,powers ,the ,commission shall have the following powers3 7#a7 ,hearings and other activities ,for the purpose of carrying out its duties1 the ,commission may hold such hearings and undertake such other activities as the ,commission determines to be necessary to carry out its duties4 7#b7 ,detail of ,federal employees ,upon the request of the ,commission1 the head of any ,federal agency is authorized to detail1 without reimbursement1 any of the personnel of such agency to the ,commission to assist the ,commission in carrying out its duties4 ,any such detail shall not interrupt or otherwise affect the civil service status or privileges of the ,federal employee4 7#c7 ,technical assistance ,upon the request of the ,commission1 the head of a ,federal agency may provide such technical assistance to the ,commission as the ,commission determines to be necessary to carry out its duties4 7#d7 ,use of mails ,the ,commission may use the ,united ,states mails in the same manner and under the same conditions as ,federal agencies4 7#e7 ,obtaining information ,the ,commission may secure directly from any ,federal agency information necessary to enable it to carry out its duties1 if the information may be disclosed under section #eeb of title #e1 ,united ,states ,code4 ,upon request of the ,chairperson of the ,commission1 the head of such agency shall furnish such information to the ,commission4 7#f7 ,administrative support services ,upon the request of the ,commission1 the ,administrator of ,general ,services shall provide to the ,commission on a reimbursable basis such administrative support services as the ,commission may request4 #g4 ,chairperson2 program managers 7a7 ,chairperson 7#a7 ,designation ,of the members of the ,commission appointed under section #e7;a71 the ,president shall at the time of the appointment1 designate one such member to serve as the ,chairperson of the ,commission4 7#b7 ,responsibilities ,the responsibilities of the ,chairperson shall include-- 7,a7 approving areas of study of the ,commission based on criteria including scientific and technical merit1 innovation1 and impact2 7,b7 developing criteria 7including benchmarks7 for assessing1 and overseeing the assessment of1 the progress of areas of study of the ,commission2 7,c7 terminating areas of study of the ,commission that are not achieving the purpose described in section #d7;a72 7,d7 designating members of the ,commission to act as program managers as described in subsection 7b72 and 7,e7 appointing staff as necessary to aid in carrying out the purpose described in section #d7;a74 7b7 ,program managers 7#a7 ,in general ,the ,chairperson of the ,commission may designate members of the ,commission who may act as program managers to oversee one or more areas of study of the ,commission4 7#b7 ,responsibilities ,a member designated under paragraph 7#a7 shall1 with respect to one or more areas of study1 be responsible for the following3 7,a7 ,recommending novel proposals1 projects1 and collaborations based on scientific and technical merit to achieve the purpose described in section #d7;a7 with a focus on strategies for the primary prevention of breast cancer1 and methods to prevent breast cancer metastasis4 ,program directors may-- 7i7 convene workshops and confer with experts in both the public and private sector2 7ii7 identify areas of study2 7iii7 identify all areas where resources could be leveraged2 and 7iv7 carry out other functions of the ,commission that are approved by the ,chairperson and that the ,chairperson deems necessary to carry out the purpose described in section #d7;a74 7,b7 ,working with relevant ,federal agencies to identify areas of concurrent interests in order to maximize ,federal investment and stimulate collaborative projects4 7,c7 ,monitoring the progress of areas of study and recommend restructure or termination4 #h4 ,coordination and nonduplication ,to the maximum extent practicable1 the ,commission shall ensure that the activities of the ,commission are coordinated with1 and do not duplicate the efforts of1 programs and laboratories of other government agencies4 #i4 ,evaluation of the ,commission 7a7 ,in general ,the ,president shall enter into an agreement with the ,institute of ,medicine of the ,national ,academy of ,sciences under which the ,institute1 after the ,commission has been in operation for #c years1 shall evaluate the ,commission's progress towards achieving the purpose described in section #d7;a74 7b7 ,inclusions ,the evaluation under subsection 7a7 shall include-- 7#a7 a recommendation on whether the ,commission should be continued or terminated2 and 7#b7 a description of lessons learned from operation of the ,commission4 7c7 ,availability ,on completion of the evaluation under subsection 7a71 the ,commission shall make the evaluation available to the ,congress and the public4 #aj4 ,authorization of funding 7a7 ,authorization of appropriations ,to carry out the purpose of this ,act1 there are authorized to be appropriated-- 7#a7 #h1jjj1jjj for fiscal year #bjac2 7#b7 #ab1jjj1jjj for each of fiscal years #bjad and #bjae2 and 7#c7 such sums as may be necessary for each fiscal year thereafter until the ,commission is terminated4 7b7 ,limitation ,none of the amounts appropriated for a fiscal year under subsection 7a7 shall be used for the operation or construction of any laboratories or pilot plants4 #aa4 ,termination ,the ,commission shall terminate on ,june #a1 #bjbj4